David J Kaczorowski

Dr. David J Kaczorowski


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NHNicholas Ryan Hess
Nicholas Ryan Hess
LZLuke A. Ziegler
Luke A. Ziegler
DKDavid J Kaczorowski
David J Kaczorowski
Heart transplantation has become the accepted treatment for advanced heart failure, with over 4000–5000 performed in the world annually. Although the number of yearly transplants performed has been increasing over the last decade, the number of candidates in need of transplantation continues to grow at an even faster rate. To distribute these scarce and precious resources equitably, donor heart placement is based on clinical need with priority given to those who are more critically ill. As a result, donors are matched with recipient candidates over increasingly farther distances, which may subject these organs to longer ischemic times. One of the mainstays of successful heart transplantation is successful organ preservation while the donor organ is ex vivo from the time of donor procurement to recipient implantation. In order to adapt to a new era of heart transplantation where organs are shared across wider ranges, preservation strategies must evolve to accommodate longer ischemia times while mitigating the harmful sequalae of ischemia-reperfusion injury. Additionally, in order to address the ever-growing supply demand mismatch of donor organs, evolving perfusion technologies may allow for further evaluation of donor grafts outside of conventional acceptance practices, thus enlarging the effective donor pool. Herein this review, we discuss the history of organ preservation, current strategies and modalities employed in current practice, along with developing technologies in preclinical stages. Lastly, we introduce the concept of donation after circulatory death (DCD), which has been until recently a largely unexplored avenue of heart donation that relies much on current preservation techniques.

15 September 2023 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
NHNicholas Ryan Hess
Nicholas Ryan Hess
YHYeahwa Hong
Yeahwa Hong
PYPyongsoo Yoon
Pyongsoo Yoon
JBJohannes Bonatti
Johannes Bonatti
ISIbrahim Sultan
Ibrahim Sultan
DKDavid J Kaczorowski
David J Kaczorowski

1 August 2021 in JTCVS Techniques
Verified
Journal Article
Open access
ASAakash Shah
Aakash Shah
SDSagar Dave
Sagar Dave
CGCorbin E. Goerlich
Corbin E. Goerlich
DKDavid J Kaczorowski
David J Kaczorowski

9 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
NHNicholas Ryan Hess
Nicholas Ryan Hess
GHGavin W. Hickey
Gavin W. Hickey
MKMary E. Keebler
Mary E. Keebler
JHJessica H. Huston
Jessica H. Huston
DMDennis M. McNamara
Dennis M. McNamara
DKDavid J Kaczorowski
David J Kaczorowski

28 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
GCGarrett Nicholas Coyan
Garrett Nicholas Coyan
NANeesha Anand
Neesha Anand
MIMahnoor Imran
Mahnoor Imran
HGHernando Gomez
Hernando Gomez
RRRaj Ramanan
Raj Ramanan
JBJohannes Bonatti
Johannes Bonatti
Background and Objectives: Post-infarct ventricular septal rupture (PIVSR) continues to have significant morbidity and mortality, despite decreased prevalence. Impella and venoarterial extracorporeal membranous oxygenation (VA-ECMO) have been proposed as strategies to correct hemodynamic derangements and bridge patients to delayed operative repair when success rates are higher. This review places VA-ECMO and Impella support strategies in the context of bridging patients to successful PIVSR repair, with an additional case report of successful bridging with the Impella device. Materials and Methods: We report a case of PIVSR repair utilizing 14 days of Impella support. We additionally conducted a systematic review of contemporary literature to describe the application of VA-ECMO and Impella devices in the pre-operative period prior to surgical PIVSR correction. Expert commentary on the advantages and disadvantages of each of these techniques is provided. Results: We identified 19 studies with 72 patients undergoing VA-ECMO as a bridge to PIVSR repair and 6 studies with 11 patients utilizing an Impella device as a bridge to PIVSR repair. Overall, outcomes in both groups were better than expected from patients who were historically managed with medicine and balloon pump therapy, however there was a significant heterogeneity between studies. Impella provided for excellent left ventricular unloading, but did result in some concerns for reversal of shunting. VA-ECMO resulted in improved end-organ perfusion, but carried increased risks of device-related complications and requirement for additional ventricular unloading. Conclusions: Patients presenting with PIVSR in cardiogenic shock requiring a MCS bridge to definitive surgical repair continue to pose a challenge to the multidisciplinary cardiovascular team as the diverse presentation and management issues require individualized care plans. Both VA-ECMO and the Impella family of devices play a role in the contemporary management of PIVSR and offer distinct advantages and disadvantages depending on the clinical scenario. The limited case numbers reported demonstrate feasibility, safety, and recommendations for optimal management.

20 January 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
YHYeahwa Hong
Yeahwa Hong
NHNicholas Ryan Hess
Nicholas Ryan Hess
LZLuke A. Ziegler
Luke A. Ziegler
GHGavin W. Hickey
Gavin W. Hickey
JHJessica H. Huston
Jessica H. Huston
DKDavid J Kaczorowski
David J Kaczorowski